董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Neil Exter | 男 | Director | 62 | 未披露 | 未持股 | 2020-12-31 |
| Laurence Reid | 男 | President and Chief Executive Officer, Director | 57 | 425.06万美元 | 未持股 | 2020-12-31 |
| Matthew Foy | 男 | Director | 40 | 未披露 | 未持股 | 2020-12-31 |
| Christine Poon | 女 | Director | 68 | 1.75万美元 | 未持股 | 2020-12-31 |
| Peter A. Thompson | 男 | Director | 61 | 未披露 | 未持股 | 2020-12-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| John Lee | 男 | Executive Vice President, Pharmaceutical Development and Interim Chief Scientific Officer | 53 | 154.64万美元 | 未持股 | 2020-12-31 |
| Laurence Reid | 男 | President and Chief Executive Officer, Director | 57 | 425.06万美元 | 未持股 | 2020-12-31 |
| Elisabeth Leiderman | 女 | Chief Financial Officer and Head of Corporate Development | 44 | 未披露 | 未持股 | 2020-12-31 |
| Anna Trask | 女 | Chief People, Community and Culture Officer | 63 | 92.21万美元 | 未持股 | 2020-12-31 |
| Ronald Vigliotta | 男 | Vice President, Finance | 47 | 未披露 | 未持股 | 2020-12-31 |
董事简历
中英对照 | 中文 | 英文- Neil Exter
-
Neil Exter，曾一直担任Third Rock Ventures公司（风险资本公司）的合伙人（2007年11月以来）。加入Third Rock Ventures公司之前，他曾担任Alantos Pharmaceuticals Holding公司的首席商务官，领导公司出售给Amgen公司，并担任Millennium Pharmaceuticals公司的副总裁，领导许可证和并购。职业生涯早期，他曾担任高技术产业的多种执行管理职务。他目前任职于REVOLUTION Medicines公司、Cibiem公司、Element Science公司、Rhythm Pharmaceuticals公司的董事会。他此前曾任职于Lotus Tissue Repair公司（被Shire公司和Seventh Sense Biosystems公司收购）的董事会。他是Children’s Hospital Boston的董事会研究委员会的成员，以及the New England Venture Capital Association的财务主管和董事会的成员。此外，他是Partners Healthcare公司的创新研究基金成员，以及Cornell University的电子与计算机工程系的顾问委员会成员。他持有Cornell University的学士学位、Stanford University的硕士学位，以及Harvard Business School的工商管理硕士学位（贝克学者）。
Neil Exter,has been a partner at Third Rock Ventures, a venture capital firm, since 2007. Prior to joining Third Rock Ventures,Mr. Exter was chief business officer of Alantos Pharmaceuticals Holding, Inc., a biopharmaceutical company, from 2006 until its acquisition by Amgen Inc. in 2007. Previously, he served as vice president of business development of Millennium Pharmaceuticals, Inc., a pharmaceutical company, from 2002 to 2006. Mr. Exter previously served as a member of the boards of directors of a number of additional publicly traded and privately held biotechnology companies, including, but not limited to, Decibel Therapeutics, Inc., a biotechnology company, Revolution Medicines Inc., a precision oncology company, and Pliant Therapeutics, Inc., a biopharmaceutical company. Mr. Exter earned a B.S. in Electrical Engineering from Cornell University, an M.S. in Electrical Engineering from Stanford University and an M.B.A. as a Baker Scholar from Harvard Business School. - Neil Exter，曾一直担任Third Rock Ventures公司（风险资本公司）的合伙人（2007年11月以来）。加入Third Rock Ventures公司之前，他曾担任Alantos Pharmaceuticals Holding公司的首席商务官，领导公司出售给Amgen公司，并担任Millennium Pharmaceuticals公司的副总裁，领导许可证和并购。职业生涯早期，他曾担任高技术产业的多种执行管理职务。他目前任职于REVOLUTION Medicines公司、Cibiem公司、Element Science公司、Rhythm Pharmaceuticals公司的董事会。他此前曾任职于Lotus Tissue Repair公司（被Shire公司和Seventh Sense Biosystems公司收购）的董事会。他是Children’s Hospital Boston的董事会研究委员会的成员，以及the New England Venture Capital Association的财务主管和董事会的成员。此外，他是Partners Healthcare公司的创新研究基金成员，以及Cornell University的电子与计算机工程系的顾问委员会成员。他持有Cornell University的学士学位、Stanford University的硕士学位，以及Harvard Business School的工商管理硕士学位（贝克学者）。
- Neil Exter,has been a partner at Third Rock Ventures, a venture capital firm, since 2007. Prior to joining Third Rock Ventures,Mr. Exter was chief business officer of Alantos Pharmaceuticals Holding, Inc., a biopharmaceutical company, from 2006 until its acquisition by Amgen Inc. in 2007. Previously, he served as vice president of business development of Millennium Pharmaceuticals, Inc., a pharmaceutical company, from 2002 to 2006. Mr. Exter previously served as a member of the boards of directors of a number of additional publicly traded and privately held biotechnology companies, including, but not limited to, Decibel Therapeutics, Inc., a biotechnology company, Revolution Medicines Inc., a precision oncology company, and Pliant Therapeutics, Inc., a biopharmaceutical company. Mr. Exter earned a B.S. in Electrical Engineering from Cornell University, an M.S. in Electrical Engineering from Stanford University and an M.B.A. as a Baker Scholar from Harvard Business School.
- Laurence Reid
-
Laurence Reid自2020年1月以来一直担任我们的总裁兼首席执行官，并担任我们的董事会成员。从2019年11月至2020年10月，他还担任我们的顾问。里德博士于2019年11月至2020年11月担任风险投资公司Third Rock Ventures的常驻企业家。2015年3月至2018年10月，他担任生物技术公司Warp Drive Bio，LLC的首席执行官。在此之前，他曾于2010年6月至2014年12月担任生物制药公司AlnylamPharmaceuticals，Inc.的首席商务官。Reid博士在剑桥大学（Cambridge University）获得自然科学学士学位，在伦敦大学国王学院（King&8217；s College）获得生物化学博士学位。
Laurence Reid has served as our president and chief executive officer and as a member of our board of directors since January 2020. He also served as a consultant to us from November 2019 until October 2020. Dr. Reid served as an entrepreneur in residence at Third Rock Ventures, a venture capital firm, from November 2019 to November 2020. From March 2015 to October 2018 he served as chief executive officer of Warp Drive Bio, LLC, a biotechnology company. Prior to that, he served as chief business officer of Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, from June 2010 to December 2014. Dr. Reid received a B.A. in natural sciences from Cambridge University and a Ph.D. in biochemistry from King’s College, London University. - Laurence Reid自2020年1月以来一直担任我们的总裁兼首席执行官，并担任我们的董事会成员。从2019年11月至2020年10月，他还担任我们的顾问。里德博士于2019年11月至2020年11月担任风险投资公司Third Rock Ventures的常驻企业家。2015年3月至2018年10月，他担任生物技术公司Warp Drive Bio，LLC的首席执行官。在此之前，他曾于2010年6月至2014年12月担任生物制药公司AlnylamPharmaceuticals，Inc.的首席商务官。Reid博士在剑桥大学（Cambridge University）获得自然科学学士学位，在伦敦大学国王学院（King&8217；s College）获得生物化学博士学位。
- Laurence Reid has served as our president and chief executive officer and as a member of our board of directors since January 2020. He also served as a consultant to us from November 2019 until October 2020. Dr. Reid served as an entrepreneur in residence at Third Rock Ventures, a venture capital firm, from November 2019 to November 2020. From March 2015 to October 2018 he served as chief executive officer of Warp Drive Bio, LLC, a biotechnology company. Prior to that, he served as chief business officer of Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, from June 2010 to December 2014. Dr. Reid received a B.A. in natural sciences from Cambridge University and a Ph.D. in biochemistry from King’s College, London University.
- Matthew Foy
-
Matthew Foy自2021年1月以来一直担任我们的董事会成员。他此前曾于2019年4月至2020年11月担任我们的董事会成员。Foy先生从2011年开始一直担任SR One Capital Management，LP的合伙人，这是一家风险投资公司。此前，Foy从2002年到2010年担任Greenhill&Co（一家投资银行）Vice President。Foy先生在牛津大学（University of Oxford）获得生物科学学士学位和硕士学位。
Matthew Foy has served as a member of our board of directors since January 2021. He previously served as a member of our board of directors from April 2019 to November 2020. Mr. Foy has been a partner at SR One Capital Management, LP, a venture capital firm, since 2011. Previously, Mr. Foy was a vice president at Greenhill & Co, an investment bank, from 2002 to 2010. Mr. Foy received BSc and MSc degrees in biological sciences from the University of Oxford. - Matthew Foy自2021年1月以来一直担任我们的董事会成员。他此前曾于2019年4月至2020年11月担任我们的董事会成员。Foy先生从2011年开始一直担任SR One Capital Management，LP的合伙人，这是一家风险投资公司。此前，Foy从2002年到2010年担任Greenhill&Co（一家投资银行）Vice President。Foy先生在牛津大学（University of Oxford）获得生物科学学士学位和硕士学位。
- Matthew Foy has served as a member of our board of directors since January 2021. He previously served as a member of our board of directors from April 2019 to November 2020. Mr. Foy has been a partner at SR One Capital Management, LP, a venture capital firm, since 2011. Previously, Mr. Foy was a vice president at Greenhill & Co, an investment bank, from 2002 to 2010. Mr. Foy received BSc and MSc degrees in biological sciences from the University of Oxford.
- Christine Poon
-
Christine Poon自2019年5月以来一直担任我们的董事会成员。Poon女士是俄亥俄州立大学马克斯·费舍尔商学院（Max M.Fisher College of Business at the Ohio State University）管理与人力资源部的常驻执行官，在那里她曾担任院长和John W.Berry，Sr.。2009年至2014年担任业务主席。从2000年到2009年，潘女士在强生公司公司（一家医疗设备，制药和消费品公司）担任越来越重要的责任和领导职务，最近担任制药副董事长兼全球董事长。潘女士自2005年以来保德信金融集团上市公司董事会任职，自2010年以来再生元制药公司上市公司董事会任职，自2014年以来宣威-威廉姆斯公司上市公司董事会任职。
Christine Poon has served as a member of our board of directors since May 2019. Ms. Poon is an executive-in-residence in the Department of Management and Human Resources at The Max M. Fisher College of Business at The Ohio State University, where she served as Dean and the John W. Berry, Sr. Chair in Business from 2009 to 2014. From 2000 to 2009 Ms. Poon held roles of increasing responsibility and leadership at Johnson & Johnson, a medical device, pharmaceutical and consumer goods company, most recently as vice chairman and worldwide chairman of pharmaceuticals. Ms. Poon has served on the boards of directors of the publicly traded companies Prudential Financial, Inc. since 2005 Regeneron Pharmaceuticals, Inc. since 2010 and The Sherwin-Williams Company since 2014. - Christine Poon自2019年5月以来一直担任我们的董事会成员。Poon女士是俄亥俄州立大学马克斯·费舍尔商学院（Max M.Fisher College of Business at the Ohio State University）管理与人力资源部的常驻执行官，在那里她曾担任院长和John W.Berry，Sr.。2009年至2014年担任业务主席。从2000年到2009年，潘女士在强生公司公司（一家医疗设备，制药和消费品公司）担任越来越重要的责任和领导职务，最近担任制药副董事长兼全球董事长。潘女士自2005年以来保德信金融集团上市公司董事会任职，自2010年以来再生元制药公司上市公司董事会任职，自2014年以来宣威-威廉姆斯公司上市公司董事会任职。
- Christine Poon has served as a member of our board of directors since May 2019. Ms. Poon is an executive-in-residence in the Department of Management and Human Resources at The Max M. Fisher College of Business at The Ohio State University, where she served as Dean and the John W. Berry, Sr. Chair in Business from 2009 to 2014. From 2000 to 2009 Ms. Poon held roles of increasing responsibility and leadership at Johnson & Johnson, a medical device, pharmaceutical and consumer goods company, most recently as vice chairman and worldwide chairman of pharmaceuticals. Ms. Poon has served on the boards of directors of the publicly traded companies Prudential Financial, Inc. since 2005 Regeneron Pharmaceuticals, Inc. since 2010 and The Sherwin-Williams Company since 2014.
- Peter A. Thompson
-
Peter A. Thompson，自2022年2月起担任Sionna Therapeutics，Inc.董事会成员。Thompson博士是投资公司OrbiMed Advisors LLC的成员，自2010年以来，他在OrbiMed Advisors LLC担任过各种职责日益增加的角色，包括2013年至2021年担任合伙人。Thompson博士目前在ARS Pharmaceuticals Inc.（前身为Silverback Therapeutics, Inc.）（NASDAQ：SPRY）董事会任职，自2016年4月起任职，Corvus Pharmaceuticals, Inc. Pharmaceuticals，Inc.（NASDAQ：CRVS），自2014年11月起任职，Edgewise Therapeutics, Inc.（NASDAQ：EWTX），自2017年5月起任职，还曾任职于多家私营公司。此前，Thompson博士曾在Alpine Immune Sciences, Inc.（纳斯达克股票代码：ALPN）、Decibel Therapeutics, Inc.（纳斯达克股票代码：DBTX）、Janux Therapeutics, Inc.（纳斯达克股票代码：JANX）、TERMVPMV Pharmaceuticals，Inc.（纳斯达克股票代码：PMVP）、Prevail Therapeutics Inc.（纳斯达克股票代码：PRVL）和Synthorx, Inc.的董事会任职，直至其被赛诺菲收购。Thompson博士此前曾在Trubion Pharmaceuticals，Inc.、Chiron Corporation和碧迪医疗公司担任行政领导职务。Thompson博士还是华盛顿大学神经外科的附属教授。此外，Thompson博士还拥有布朗大学分子生物学和数学理学学士学位和布朗大学医学院医学博士学位。
Peter A. Thompson,has served as a member of Sionna Therapeutics, Inc. board of directors since February 2022. Dr. Thompson is a member at OrbiMed Advisors LLC, an investment firm, where he has served in various roles of increasing responsibility since 2010, including as Partner from 2013 to 2021. Dr. Thompson currently serves on the boards of directors of ARS Pharmaceuticals Inc. (formerly Silverback Therapeutics, Inc.) (NASDAQ: SPRY), since April 2016, Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), since November 2014, and Edgewise Therapeutics, Inc. (NASDAQ: EWTX), since May 2017, as well as several private companies. Previously, Dr. Thompson served on the boards of directors of Alpine Immune Sciences, Inc. (NASDAQ: ALPN), Decibel Therapeutics, Inc. (NASDAQ: DBTX), Janux Therapeutics, Inc. (NASDAQ: JANX), PMV Pharmaceuticals, Inc. (NASDAQ: PMVP), Prevail Therapeutics Inc. (NASDAQ: PRVL) and Synthorx, Inc., until its acquisition by Sanofi. Dr. Thompson previously served in executive leadership roles at Trubion Pharmaceuticals, Inc., Chiron Corporation and Becton, Dickinson and Company. Dr. Thompson is also an Affiliate Professor of Neurosurgery at the University of Washington. In addition, Dr. Thompson holds a Sc. B. in Molecular Biology and Mathematics from Brown University and an M.D. from Brown University Medical School. - Peter A. Thompson，自2022年2月起担任Sionna Therapeutics，Inc.董事会成员。Thompson博士是投资公司OrbiMed Advisors LLC的成员，自2010年以来，他在OrbiMed Advisors LLC担任过各种职责日益增加的角色，包括2013年至2021年担任合伙人。Thompson博士目前在ARS Pharmaceuticals Inc.（前身为Silverback Therapeutics, Inc.）（NASDAQ：SPRY）董事会任职，自2016年4月起任职，Corvus Pharmaceuticals, Inc. Pharmaceuticals，Inc.（NASDAQ：CRVS），自2014年11月起任职，Edgewise Therapeutics, Inc.（NASDAQ：EWTX），自2017年5月起任职，还曾任职于多家私营公司。此前，Thompson博士曾在Alpine Immune Sciences, Inc.（纳斯达克股票代码：ALPN）、Decibel Therapeutics, Inc.（纳斯达克股票代码：DBTX）、Janux Therapeutics, Inc.（纳斯达克股票代码：JANX）、TERMVPMV Pharmaceuticals，Inc.（纳斯达克股票代码：PMVP）、Prevail Therapeutics Inc.（纳斯达克股票代码：PRVL）和Synthorx, Inc.的董事会任职，直至其被赛诺菲收购。Thompson博士此前曾在Trubion Pharmaceuticals，Inc.、Chiron Corporation和碧迪医疗公司担任行政领导职务。Thompson博士还是华盛顿大学神经外科的附属教授。此外，Thompson博士还拥有布朗大学分子生物学和数学理学学士学位和布朗大学医学院医学博士学位。
- Peter A. Thompson,has served as a member of Sionna Therapeutics, Inc. board of directors since February 2022. Dr. Thompson is a member at OrbiMed Advisors LLC, an investment firm, where he has served in various roles of increasing responsibility since 2010, including as Partner from 2013 to 2021. Dr. Thompson currently serves on the boards of directors of ARS Pharmaceuticals Inc. (formerly Silverback Therapeutics, Inc.) (NASDAQ: SPRY), since April 2016, Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), since November 2014, and Edgewise Therapeutics, Inc. (NASDAQ: EWTX), since May 2017, as well as several private companies. Previously, Dr. Thompson served on the boards of directors of Alpine Immune Sciences, Inc. (NASDAQ: ALPN), Decibel Therapeutics, Inc. (NASDAQ: DBTX), Janux Therapeutics, Inc. (NASDAQ: JANX), PMV Pharmaceuticals, Inc. (NASDAQ: PMVP), Prevail Therapeutics Inc. (NASDAQ: PRVL) and Synthorx, Inc., until its acquisition by Sanofi. Dr. Thompson previously served in executive leadership roles at Trubion Pharmaceuticals, Inc., Chiron Corporation and Becton, Dickinson and Company. Dr. Thompson is also an Affiliate Professor of Neurosurgery at the University of Washington. In addition, Dr. Thompson holds a Sc. B. in Molecular Biology and Mathematics from Brown University and an M.D. from Brown University Medical School.
高管简历
中英对照 | 中文 | 英文- John Lee
John Lee自2018年10月起担任公司医药开发执行Vice President，自2020年1月起担任公司临时首席科学官。此前，他曾担任我们的高级副总裁，制药开发（2016年9月以来）。在加入我们之前，他在生物制药公司InfinityPharmaceuticals，Inc.担任了超过15年的责任和领导职务，最终于2006年至2016年9月担任高级副总裁，制药开发。Lee先生在麻省理工学院（Massachusetts Institute of Technology）获得材料科学与工程学士学位。
John Lee has served as our executive vice president, pharmaceutical development since October 2018 and our interim chief scientific officer since January 2020. Previously, he served as our senior vice president, pharmaceutical development since September 2016. Prior to joining us, he held roles of increasing responsibility and leadership over 15 years at Infinity Pharmaceuticals, Inc., a biopharmaceutical company, ultimately serving as senior vice president, pharmaceutical development from 2006 to September 2016. Mr. Lee received a B.A. in materials science and engineering from the Massachusetts Institute of Technology.- John Lee自2018年10月起担任公司医药开发执行Vice President，自2020年1月起担任公司临时首席科学官。此前，他曾担任我们的高级副总裁，制药开发（2016年9月以来）。在加入我们之前，他在生物制药公司InfinityPharmaceuticals，Inc.担任了超过15年的责任和领导职务，最终于2006年至2016年9月担任高级副总裁，制药开发。Lee先生在麻省理工学院（Massachusetts Institute of Technology）获得材料科学与工程学士学位。
- John Lee has served as our executive vice president, pharmaceutical development since October 2018 and our interim chief scientific officer since January 2020. Previously, he served as our senior vice president, pharmaceutical development since September 2016. Prior to joining us, he held roles of increasing responsibility and leadership over 15 years at Infinity Pharmaceuticals, Inc., a biopharmaceutical company, ultimately serving as senior vice president, pharmaceutical development from 2006 to September 2016. Mr. Lee received a B.A. in materials science and engineering from the Massachusetts Institute of Technology.
- Laurence Reid
Laurence Reid自2020年1月以来一直担任我们的总裁兼首席执行官，并担任我们的董事会成员。从2019年11月至2020年10月，他还担任我们的顾问。里德博士于2019年11月至2020年11月担任风险投资公司Third Rock Ventures的常驻企业家。2015年3月至2018年10月，他担任生物技术公司Warp Drive Bio，LLC的首席执行官。在此之前，他曾于2010年6月至2014年12月担任生物制药公司AlnylamPharmaceuticals，Inc.的首席商务官。Reid博士在剑桥大学（Cambridge University）获得自然科学学士学位，在伦敦大学国王学院（King&8217；s College）获得生物化学博士学位。
Laurence Reid has served as our president and chief executive officer and as a member of our board of directors since January 2020. He also served as a consultant to us from November 2019 until October 2020. Dr. Reid served as an entrepreneur in residence at Third Rock Ventures, a venture capital firm, from November 2019 to November 2020. From March 2015 to October 2018 he served as chief executive officer of Warp Drive Bio, LLC, a biotechnology company. Prior to that, he served as chief business officer of Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, from June 2010 to December 2014. Dr. Reid received a B.A. in natural sciences from Cambridge University and a Ph.D. in biochemistry from King’s College, London University.- Laurence Reid自2020年1月以来一直担任我们的总裁兼首席执行官，并担任我们的董事会成员。从2019年11月至2020年10月，他还担任我们的顾问。里德博士于2019年11月至2020年11月担任风险投资公司Third Rock Ventures的常驻企业家。2015年3月至2018年10月，他担任生物技术公司Warp Drive Bio，LLC的首席执行官。在此之前，他曾于2010年6月至2014年12月担任生物制药公司AlnylamPharmaceuticals，Inc.的首席商务官。Reid博士在剑桥大学（Cambridge University）获得自然科学学士学位，在伦敦大学国王学院（King&8217；s College）获得生物化学博士学位。
- Laurence Reid has served as our president and chief executive officer and as a member of our board of directors since January 2020. He also served as a consultant to us from November 2019 until October 2020. Dr. Reid served as an entrepreneur in residence at Third Rock Ventures, a venture capital firm, from November 2019 to November 2020. From March 2015 to October 2018 he served as chief executive officer of Warp Drive Bio, LLC, a biotechnology company. Prior to that, he served as chief business officer of Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, from June 2010 to December 2014. Dr. Reid received a B.A. in natural sciences from Cambridge University and a Ph.D. in biochemistry from King’s College, London University.
- Elisabeth Leiderman
Elisabeth Leiderman自2020年9月起担任我们的首席财务官兼企业发展主管。从2020年1月至2020年8月，Leiderman博士担任生物制药公司Complexa，Inc.的首席商务官。2016年11月至2019年11月，她担任生物制药公司FortressBiotech，Inc.的企业发展高级副总裁，主管。她曾于2007年至2016年担任梦百合投资银行家。最近，她于2013年至2016年7月担任投资银行野村证券（Nomura Securities）的执行董事。Leiderman博士在宾夕法尼亚大学（University of Pennsylvania）获得生物科学学士学位，在宾夕法尼亚大学沃顿商学院（Wharton School of the University of Pennsylvania）获得工商管理硕士学位，在特拉维夫大学（Tel Aviv University）萨克勒医学院（Sackler School of Medicine）获得医学博士学位。
Elisabeth Leiderman has served as our chief financial officer and head of corporate development since September 2020. From January 2020 to August 2020 Dr. Leiderman served as chief business officer at Complexa, Inc., a biopharmaceutical company. From November 2016 to November 2019 she was senior vice president, head of corporate development at Fortress Biotech, Inc., a biopharmaceutical company. She was a healthcare investment banker from 2007 to 2016. Most recently, she was an executive director at Nomura Securities, an investment bank, from 2013 to July 2016. Dr. Leiderman received a B.A. in biological sciences from the University of Pennsylvania, an M.B.A. from The Wharton School of the University of Pennsylvania and an M.D. from the Sackler School of Medicine at Tel Aviv University.- Elisabeth Leiderman自2020年9月起担任我们的首席财务官兼企业发展主管。从2020年1月至2020年8月，Leiderman博士担任生物制药公司Complexa，Inc.的首席商务官。2016年11月至2019年11月，她担任生物制药公司FortressBiotech，Inc.的企业发展高级副总裁，主管。她曾于2007年至2016年担任梦百合投资银行家。最近，她于2013年至2016年7月担任投资银行野村证券（Nomura Securities）的执行董事。Leiderman博士在宾夕法尼亚大学（University of Pennsylvania）获得生物科学学士学位，在宾夕法尼亚大学沃顿商学院（Wharton School of the University of Pennsylvania）获得工商管理硕士学位，在特拉维夫大学（Tel Aviv University）萨克勒医学院（Sackler School of Medicine）获得医学博士学位。
- Elisabeth Leiderman has served as our chief financial officer and head of corporate development since September 2020. From January 2020 to August 2020 Dr. Leiderman served as chief business officer at Complexa, Inc., a biopharmaceutical company. From November 2016 to November 2019 she was senior vice president, head of corporate development at Fortress Biotech, Inc., a biopharmaceutical company. She was a healthcare investment banker from 2007 to 2016. Most recently, she was an executive director at Nomura Securities, an investment bank, from 2013 to July 2016. Dr. Leiderman received a B.A. in biological sciences from the University of Pennsylvania, an M.B.A. from The Wharton School of the University of Pennsylvania and an M.D. from the Sackler School of Medicine at Tel Aviv University.
- Anna Trask
Anna Trask自2018年1月起担任我们的首席人力，社区和文化官。2012年11月至2016年12月，Trask女士担任Dana-Farber Cancer Institute人力资源高级总监。Trask女士在Mount Holyoke College获得政治学学士学位，在Boston University获得心理学硕士学位。
Anna Trask has served as our chief people, community and culture officer since January 2018. From November 2012 to December 2016 Ms. Trask served as senior director, human resources at the Dana-Farber Cancer Institute. Ms. Trask received a B.A. in politics from Mount Holyoke College and an M.A. in psychology from Boston University.- Anna Trask自2018年1月起担任我们的首席人力，社区和文化官。2012年11月至2016年12月，Trask女士担任Dana-Farber Cancer Institute人力资源高级总监。Trask女士在Mount Holyoke College获得政治学学士学位，在Boston University获得心理学硕士学位。
- Anna Trask has served as our chief people, community and culture officer since January 2018. From November 2012 to December 2016 Ms. Trask served as senior director, human resources at the Dana-Farber Cancer Institute. Ms. Trask received a B.A. in politics from Mount Holyoke College and an M.A. in psychology from Boston University.
- Ronald Vigliotta
Ronald Vigliotta自2018年11月起担任我们的财务Vice President。此前，他曾担任我们的高级财务总监（2016年11月以来）。2013年至2016年11月，Vigliotta先生担任Warp Drive Bio，LLC（一家生物技术公司）的财务总监。他此前曾任职Ernst&Young LLP（会计师事务所）。Vigliotta先生在费尔菲尔德大学（Fairfield University）获得会计与金融学学士学位。Vigliotta先生是一名注册会计师。
Ronald Vigliotta has served as our vice president, finance since November 2018. Previously, he served as our senior director, finance since November 2016. From 2013 to November 2016 Mr. Vigliotta served as controller at Warp Drive Bio, LLC, a biotechnology company. He previously worked at Ernst & Young LLP, an accounting firm. Mr. Vigliotta received a B.S. in accounting and finance from Fairfield University. Mr. Vigliotta is a certified public accountant.- Ronald Vigliotta自2018年11月起担任我们的财务Vice President。此前，他曾担任我们的高级财务总监（2016年11月以来）。2013年至2016年11月，Vigliotta先生担任Warp Drive Bio，LLC（一家生物技术公司）的财务总监。他此前曾任职Ernst&Young LLP（会计师事务所）。Vigliotta先生在费尔菲尔德大学（Fairfield University）获得会计与金融学学士学位。Vigliotta先生是一名注册会计师。
- Ronald Vigliotta has served as our vice president, finance since November 2018. Previously, he served as our senior director, finance since November 2016. From 2013 to November 2016 Mr. Vigliotta served as controller at Warp Drive Bio, LLC, a biotechnology company. He previously worked at Ernst & Young LLP, an accounting firm. Mr. Vigliotta received a B.S. in accounting and finance from Fairfield University. Mr. Vigliotta is a certified public accountant.